ATR Inhibitors in Platinum-Resistant Ovarian Cancer

SIMPLE SUMMARY: Platinum-resistant ovarian cancer (PROC) is a deadly cancer with a poor prognosis. Some drugs targeting ATR have shown initial success in the treatment of PROC. Therefore, we reviewed the mechanism of the ATR pathway, the results of preclinical and clinical trials in PROC, and potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Siyu, Wang, Tao, Fei, Xichang, Zhang, Mingjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740197/
https://www.ncbi.nlm.nih.gov/pubmed/36497387
http://dx.doi.org/10.3390/cancers14235902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740197/
https://www.ncbi.nlm.nih.gov/pubmed/36497387
http://dx.doi.org/10.3390/cancers14235902

Ejemplares similares